Drugs to prevent stroke and dementia show promise in early trial
Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study. The drugs - called cilostazol and isosorbide mononitrate - are already used to treat other conditions, such as heart disease and angina. This is the first time they have been tested in the UK for the treatment of stroke or vascular dementia. (Source: World Pharma News)
Source: World Pharma News - April 29, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

cilostazol (Pletal)
Title: cilostazol (Pletal)Category: MedicationsCreated: 4/17/1999 12:00:00 AMLast Editorial Review: 3/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 19, 2019 Category: Cardiology Source Type: news

Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke Dual Antiplatelet Therapy With Cilostazol Cuts Recurrent Stroke
New results show cilostazol plus aspirin or clopidogrel reduced recurrent stroke rate by half over aspirin or clopidogrel alone in high-risk stroke patients without increased bleeding.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Blood Thinning Drug May Be Safer Option Against Recurrent Stroke
THURSDAY, Feb. 7, 2019 -- Taking the blood thinner Pletal (cilostazol) with either aspirin or clopidogrel (best known as Plavix) lowers stroke patients'risk of a subsequent stroke better than taking aspirin or clopidogrel alone, a new study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 7, 2019 Category: General Medicine Source Type: news

Cilostazol Works in DAPT for Secondary Stroke Prevention
(MedPage Today) --'Fantastic result'with phosphodiesterase-3 inhibitor (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 7, 2019 Category: Primary Care Source Type: news

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
(American Heart Association) The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2019 Category: International Medicine & Public Health Source Type: news

Quality of care for peripheral artery disease is low
This study is a “call to action” to identify and implement effective physician-targeted and patient-targeted strategies aimed at improving quality of care. These strategies should take advantage of recent advances in behavior change, including leveraging an individual’s social support network to help them mak e lifestyle changes, and providing physicians with feedback about the quality of care they provide to patients with peripheral artery disease.AUTHORSJoseph Ladapo of UCLA and Jeffrey Berger of New York University.JOURNALThe studyis published online by the Journal of the American College of Cardi...
Source: UCLA Newsroom: Health Sciences - May 1, 2017 Category: Universities & Medical Training Source Type: news

Cilostazol: An Option for Ischemic Stroke After ICH? Cilostazol: An Option for Ischemic Stroke After ICH?
The antiplatelet agent cilostazol showed promising results among this difficult-to-treat group in the PICASSO trial.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 2, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Cilostazol Fails to Best Aspirin for Post-Stroke Secondary Prevention (CME/CE)
(MedPage Today) -- Non-inferior overall but MI rates higher with PDE3 inhibitor (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 25, 2017 Category: Geriatrics Source Type: news

Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2016 Category: Drugs & Pharmacology Source Type: news

Cilostazol Bridges Surgical DES Patients Without DAPTCilostazol Bridges Surgical DES Patients Without DAPT
Based on long-term follow-up in an observational study, the PDE-3 inhibitor was called an "ingenious bridge" for patients taken off standard dual-antiplatelet therapy during surgery. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 12, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Pletal (Cilostazol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 13, 2015 Category: Drugs & Pharmacology Source Type: news

Two Antiplatelet Add-on Regimens About Equal (CME/CE)
(MedPage Today) -- Adding cilostazol (Pletal) to standard dual antiplatelet therapy performed as well as doubling the dose of clopidogrel (Plavix) after implantation of a drug-eluting stent, the HOST-ASSURE study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 17, 2013 Category: Cardiology Source Type: news

EMA recommends restricting cilostazol use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants. (Source: theHeart.org)
Source: theHeart.org - March 22, 2013 Category: Cardiology Source Type: news

EMA Recommends Restricting Cilostazol Use for PADEMA Recommends Restricting Cilostazol Use for PAD
The Europeans Medicines Agency has recommended restricting the use of cilostazol in patients with intermittent claudication. Use should be avoided in those with cardiac problems or on dual anticoagulants News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

EU medicines agency to restrict use of Otsuka drug
LONDON (Reuters) - The European Medicines Agency said on Friday it was recommending restricting the use of medicines containing cilostazol, sold by Otsuka under the brand name Pletal, following concerns over side effects. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

European Medicines Agency recommends restricting use of cilostazol-containing medicines
Source: EMA Area: News Following a review of the current evidence, the European Medicines Agency's (EMA) Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol in the treatment of intermittent claudication should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.   The Spanish Agency for Medicines and Health Products (AEMPS) asked the CHMP to carry out a review of cilostazol following a number of reports of serious suspected adverse effects, in particular ...
Source: NeLM - Cardiovascular Medicine - March 22, 2013 Category: Cardiology Source Type: news